Literature DB >> 16893989

Association of CD14 promoter polymorphism with otitis media and pneumococcal vaccine responses.

S P Wiertsema1, S-K Khoo, G Baynam, R H Veenhoven, I A Laing, G A Zielhuis, G T Rijkers, J Goldblatt, P N Lesouëf, E A M Sanders.   

Abstract

Innate immunity is of particular importance for protection against infection during early life, when adaptive immune responses are immature. CD14 plays key roles in innate immunity, including in defense against pathogens associated with otitis media, a major pediatric health care issue. The T allele of the CD14 C-159T polymorphism has been associated with increased serum CD14 levels. Our objective was to investigate the hypothesis that the CD14 C-159T allele is protective against recurrent acute otitis media in children. The association between the CD14 promoter genotype and the number of acute otitis media episodes was evaluated both retrospectively and prospectively in a cohort of 300 children. Serotype-specific immunoglobulin G (IgG) antibody responses after pneumococcal vaccinations were examined according to CD14 genotype to compare immune responsiveness across genotypes. An age-dependent association was found: compared with that for CC homozygotes aged between 12 to 24 months, TT homozygotes had fewer episodes of acute otitis media (79 versus 41%, respectively; P = 0.004); this relationship was absent in older children. Additionally, TT homozygotes showed higher serotype-specific anti-pneumococcal IgG antibody levels. Our data suggest that genetic variation in CD14, a molecule at the interface of innate and adaptive immune responses, plays a key role in the defense against middle ear disease in childhood and in pneumococcal vaccine responsiveness. These findings are likely to be important to these and other immune-mediated outcomes in early life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893989      PMCID: PMC1539116          DOI: 10.1128/CVI.00100-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  54 in total

1.  Learning from discrepancies: CD14 polymorphisms, atopy and the endotoxin switch.

Authors:  D Vercelli
Journal:  Clin Exp Allergy       Date:  2003-02       Impact factor: 5.018

Review 2.  How we detect microbes and respond to them: the Toll-like receptors and their transducers.

Authors:  B Beutler; K Hoebe; X Du; R J Ulevitch
Journal:  J Leukoc Biol       Date:  2003-07-01       Impact factor: 4.962

Review 3.  Toll receptors, CD14, and macrophage activation and deactivation by LPS.

Authors:  Marina A Dobrovolskaia; Stefanie N Vogel
Journal:  Microbes Infect       Date:  2002-07       Impact factor: 2.700

4.  A comprehensive model for the aetiology of otitis media with effusion.

Authors:  M Straetemans; N van Heerbeek; E Tonnaer; K J Ingels; G T Rijkers; G A Zielhuis
Journal:  Med Hypotheses       Date:  2001-12       Impact factor: 1.538

5.  Deficient IgA and IgG2 anti-pneumococcal antibody levels and response to vaccination in otitis prone children.

Authors:  Ingeborg J Dhooge; Muriel J P van Kempen; Lieke A M Sanders; Ger T Rijkers
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2002-06-17       Impact factor: 1.675

6.  Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study.

Authors:  Reinier Veenhoven; Debby Bogaert; Cuno Uiterwaal; Carole Brouwer; Herma Kiezebrink; Jacob Bruin; Ed IJzerman; Peter Hermans; Ronald de Groot; Ben Zegers; Wietse Kuis; Ger Rijkers; Anne Schilder; Elisabeth Sanders
Journal:  Lancet       Date:  2003-06-28       Impact factor: 79.321

Review 7.  The role of mannose-binding lectin in health and disease.

Authors:  M W Turner
Journal:  Mol Immunol       Date:  2003-11       Impact factor: 4.407

Review 8.  Immunology of bacterial polysaccharide antigens.

Authors:  Andrej Weintraub
Journal:  Carbohydr Res       Date:  2003-11-14       Impact factor: 2.104

9.  Pyogenic bacterial infections in humans with IRAK-4 deficiency.

Authors:  Capucine Picard; Anne Puel; Marion Bonnet; Cheng-Lung Ku; Jacinta Bustamante; Kun Yang; Claire Soudais; Stéphanie Dupuis; Jacqueline Feinberg; Claire Fieschi; Carole Elbim; Remi Hitchcock; David Lammas; Graham Davies; Abdulaziz Al-Ghonaium; Hassan Al-Rayes; Sulaiman Al-Jumaah; Sami Al-Hajjar; Ibrahim Zaid Al-Mohsen; Husn H Frayha; Rajivi Rucker; Thomas R Hawn; Alan Aderem; Haysam Tufenkeji; Soichi Haraguchi; Noorbibi K Day; Robert A Good; Marie-Anne Gougerot-Pocidalo; Adrian Ozinsky; Jean-Laurent Casanova
Journal:  Science       Date:  2003-03-13       Impact factor: 47.728

10.  A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.

Authors:  Gilles Courtois; Asma Smahi; Janine Reichenbach; Rainer Döffinger; Caterina Cancrini; Marion Bonnet; Anne Puel; Christine Chable-Bessia; Shoji Yamaoka; Jacqueline Feinberg; Sophie Dupuis-Girod; Christine Bodemer; Susanna Livadiotti; Francesco Novelli; Paolo Rossi; Alain Fischer; Alain Israël; Arnold Munnich; Françoise Le Deist; Jean-Laurent Casanova
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

View more
  21 in total

1.  CC chemokine ligand 3 overcomes the bacteriocidal and phagocytic defect of macrophages and hastens recovery from experimental otitis media in TNF-/- mice.

Authors:  Anke Leichtle; Michelle Hernandez; Joerg Ebmeyer; Kenshi Yamasaki; Yuping Lai; Katherine Radek; Yun-Hoon Choung; Sara Euteneuer; Kwang Pak; Richard Gallo; Stephen I Wasserman; Allen F Ryan
Journal:  J Immunol       Date:  2010-02-17       Impact factor: 5.422

2.  Association of cytokine gene polymorphisms and risk factors with otitis media proneness in children.

Authors:  Olivera Miljanović; Bojana Cikota-Aleksić; Dragan Likić; Danilo Vojvodić; Ognjen Jovićević; Zvonko Magić
Journal:  Eur J Pediatr       Date:  2016-03-09       Impact factor: 3.183

Review 3.  Current knowledge of the genetics of otitis media.

Authors:  Lena Hafrén; Erna Kentala; Elisabet Einarsdottir; Juha Kere; Petri S Mattila
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

4.  TLR4-mediated induction of TLR2 signaling is critical in the pathogenesis and resolution of otitis media.

Authors:  Anke Leichtle; Michelle Hernandez; Kwang Pak; Kenshi Yamasaki; Chun-Fang Cheng; Nicholas J Webster; Allen F Ryan; Stephen I Wasserman
Journal:  Innate Immun       Date:  2009-07-08       Impact factor: 2.680

Review 5.  CD14, endotoxin, and asthma risk: actions and interactions.

Authors:  Fernando D Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-07

Review 6.  Unraveling the genetics of otitis media: from mouse to human and back again.

Authors:  Marie S Rye; Mahmood F Bhutta; Michael T Cheeseman; David Burgner; Jenefer M Blackwell; Steve D M Brown; Sarra E Jamieson
Journal:  Mamm Genome       Date:  2010-11-25       Impact factor: 2.957

Review 7.  Innate signaling in otitis media: pathogenesis and recovery.

Authors:  Anke Leichtle; Yuping Lai; Barbara Wollenberg; Stephen I Wasserman; Allen F Ryan
Journal:  Curr Allergy Asthma Rep       Date:  2011-02       Impact factor: 4.806

8.  Evaluation of 15 functional candidate genes for association with chronic otitis media with effusion and/or recurrent otitis media (COME/ROM).

Authors:  Michèle M Sale; Wei-Min Chen; Daniel E Weeks; Josyf C Mychaleckyj; Xuanlin Hou; Miranda Marion; Fernando Segade; Margaretha L Casselbrant; Ellen M Mandel; Robert E Ferrell; Stephen S Rich; Kathleen A Daly
Journal:  PLoS One       Date:  2011-08-16       Impact factor: 3.240

9.  The toll-Like receptor adaptor TRIF contributes to otitis media pathogenesis and recovery.

Authors:  Anke Leichtle; Michelle Hernandez; Kwang Pak; Nicholas J Webster; Stephen I Wasserman; Allen F Ryan
Journal:  BMC Immunol       Date:  2009-08-05       Impact factor: 3.615

Review 10.  Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.

Authors:  Luke A J O'Neill; Clare E Bryant; Sarah L Doyle
Journal:  Pharmacol Rev       Date:  2009-05-27       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.